7.91
-0.29 (-3.54%)
| Previous Close | 8.20 |
| Open | 8.34 |
| Volume | 967,985 |
| Avg. Volume (3M) | 2,921,656 |
| Market Cap | 467,544,512 |
| Price / Earnings (Forward) | 103.09 |
| Price / Sales | 1.48 |
| Price / Book | 0.630 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | -21.98% |
| Operating Margin (TTM) | -81.99% |
| Diluted EPS (TTM) | -0.760 |
| Quarterly Revenue Growth (YOY) | 5.40% |
| Total Debt/Equity (MRQ) | 2.30% |
| Current Ratio (MRQ) | 3.92 |
| Operating Cash Flow (TTM) | -56.47 M |
| Levered Free Cash Flow (TTM) | -41.71 M |
| Return on Assets (TTM) | -7.05% |
| Return on Equity (TTM) | -8.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vanda Pharmaceuticals Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.30 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.16% |
| % Held by Institutions | 78.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Krensavage Asset Management, Llc | 31 Dec 2025 | 1,180,388 |
| Empire Financial Management Company, Llc | 31 Dec 2025 | 1,108,245 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (HC Wainwright & Co., 203.41%) | Buy |
| Median | 16.00 (102.28%) | |
| Low | 7.50 (Jefferies, -5.18%) | Hold |
| Average | 15.88 (100.76%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 8.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 05 Mar 2026 | 18.00 (127.56%) | Buy | 7.91 |
| HC Wainwright & Co. | 23 Feb 2026 | 24.00 (203.41%) | Buy | 8.15 |
| 05 Jan 2026 | 22.00 (178.13%) | Buy | 7.87 | |
| B. Riley Securities | 31 Dec 2025 | 14.00 (76.99%) | Buy | 8.82 |
| Jefferies | 31 Dec 2025 | 7.50 (-5.18%) | Hold | 8.82 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BIRZNIEKS GUNTHER | - | 8.17 | -42,431 | -346,661 |
| MORAN KEVIN PATRICK | - | 8.17 | -42,442 | -346,751 |
| POLYMEROPOULOS MIHAEL HRISTOS | - | 8.17 | -156,235 | -1,276,440 |
| WIJKSTROM JOAKIM | - | 8.17 | -30,800 | -251,636 |
| WILLIAMS TIMOTHY | - | 8.17 | -42,434 | -346,686 |
| Aggregate Net Quantity | -314,342 | |||
| Aggregate Net Value ($) | -2,568,174 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 8.17 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BIRZNIEKS GUNTHER | Officer | 02 Mar 2026 | Sell (-) | 42,431 | 8.17 | 346,661 |
| POLYMEROPOULOS MIHAEL HRISTOS | Officer | 02 Mar 2026 | Sell (-) | 156,235 | 8.17 | 1,276,440 |
| WIJKSTROM JOAKIM | Officer | 02 Mar 2026 | Sell (-) | 30,800 | 8.17 | 251,636 |
| MORAN KEVIN PATRICK | Officer | 02 Mar 2026 | Sell (-) | 42,442 | 8.17 | 346,751 |
| WILLIAMS TIMOTHY | Officer | 02 Mar 2026 | Sell (-) | 42,434 | 8.17 | 346,686 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |